LabNow Vice President Joe Skraba to present at "Investment In Innovation -In3-: A Preview of Early-Stage Medical Technology Companies"

LabNow Vice President Joe Skraba to present at "Investment In Innovation -In3-: A Preview of Early-Stage Medical Technology Companies"

Business Wire - June 13, 2005

SAN FRANCISCO -- Joe Skraba, VP of Business Development at LabNow will be presenting information on the LabNow Analyzer and BioChip System at Investment In Innovation (In3). The system is capable of performing rapid, low cost cellular and chemical assays at the point of care. The company, headquartered in Austin, Texas, has an exclusive, world-wide license for all applications of the novel, platform lab-on-a-chip sensor technology from The University of Texas at Austin. The technology has the capability to automate complex fluid analysis quickly, accurately and at lower cost than current methods. The microfluidics sensor technology has broad uses in medical, homeland security, environmental chemistry and process engineering applications. Mr. Skraba will be highlighting advances made by the company in HIV/AIDS monitoring and Cardiac Risk factor detection.

Technology Description

LabNow's initial focus is on point-of-care testing markets for in vitro diagnostic applications. In collaboration between UT and Massachusetts General Hospital (MGH) a prototype test system was developed and evaluated for rapid analysis of key blood measurements in HIV/AIDS patients. This measurement, CD4 lymphocyte count, is a key indicator of disease progression and is used to determine whether drug treatment is initiated or modified. The prototype CD4 test has been shown to statistically correlate with the current gold standard test conducted on state-of-the-art flow cytometry equipment.

The LabNow CD4 System has the ability to revolutionize the monitoring of treatment for HIV/AIDS patients. The test is conducted in a disposable microfluidics biochip in conjunction with a portable analyzer. The LabNow CD4 BioChip could be used in developed healthcare markets or in resource scarce countries. This system is being designed to have significant advantages over current measurement methods.

http://www.labnow.com

About In3

This two-day event will highlight emerging technologies being developed by more than 50 small, mostly privately-held medical technology companies seeking strategic partners and/or investment. The meeting will draw an attendance of over 350 senior executives from the investment community and major medical technology, biopharmaceutical, biotech, and other companies.

CONTACT: LabNow

Stephen Ceresia, 512.329.9998 x211

sceresia@labnow.com

SOURCE: LabNow

050613
BW050611

Copyright © 2005 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .